Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease

Tumour necrosis factor (TNF)‐antagonists have an established role in the treatment of inflammatory bowel diseases (IBDs), however, subtherapeutic drug levels and the formation of anti‐drug antibodies (ADAs) may decrease their efficacy.

[1]  W. Sandborn,et al.  A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  P. Rutgeerts,et al.  Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient , 2013, The American Journal of Gastroenterology.

[3]  W. Sandborn,et al.  Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  Sharat Singh,et al.  Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. , 2012, Journal of immunological methods.

[5]  B. Pariente,et al.  Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease , 2012, Inflammatory bowel diseases.

[6]  S. Targan,et al.  Abatacept for Crohn's disease and ulcerative colitis. , 2012, Gastroenterology.

[7]  L. Croner,et al.  565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD) , 2012 .

[8]  P. Rutgeerts,et al.  566 Infliximab Concentration and Clinical Outcome in Patients With Ulcerative Colitis , 2012 .

[9]  M. Silverberg,et al.  Sa2047 Association of Serum Infliximab and Antibodies to Infliximab to Long-Term Clinical Outcome in Acute Ulcerative Colitis , 2012 .

[10]  J. Gisbert,et al.  Systematic review: antibodies and anti‐TNF‐α levels in inflammatory bowel disease , 2012, Alimentary pharmacology & therapeutics.

[11]  D. Mould,et al.  Anti‐TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics‐Based Dosing Paradigms , 2012, Clinical pharmacology and therapeutics.

[12]  G. Van Assche,et al.  Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease , 2012, Inflammatory bowel diseases.

[13]  P. Lakatos,et al.  Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use? , 2012, Expert opinion on biological therapy.

[14]  S. Danese.  New therapies for inflammatory bowel disease: from the bench to the bedside , 2011, Gut.

[15]  P. Rutgeerts,et al.  Early Serum Infliximab Trough Level, Clinical Disease Activity and CRP as Markers of Sustained Benefit of Infliximab Treatment in Crohnʼs Disease: A Post-hoc Analysis of the ACCENT1 Trial: 1226 , 2011 .

[16]  Honghui Zhou,et al.  Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. , 2011, Clinical therapeutics.

[17]  S. Ben-Horin,et al.  Review article: loss of response to anti‐TNF treatments in Crohn’s disease , 2011, Alimentary pharmacology & therapeutics.

[18]  W. Reinisch,et al.  Review article: infliximab for Crohn’s disease treatment – shifting therapeutic strategies after 10 years of clinical experience , 2011, Alimentary pharmacology & therapeutics.

[19]  U. Kopylov,et al.  The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab , 2011, Alimentary pharmacology & therapeutics.

[20]  B. Dijkmans,et al.  The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept , 2010, Annals of the rheumatic diseases.

[21]  A. Watson,et al.  Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis , 2010, Gut.

[22]  Yasuo Suzuki,et al.  Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti‐TNF , 2010, Inflammatory bowel diseases.

[23]  W. Sandborn,et al.  Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.

[24]  A. Cohen,et al.  S1051 Methotrexate for the Prevention of Antibodies to Infliximab in Patients With Crohn's Disease , 2010 .

[25]  A. Olson,et al.  Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. , 2010, International journal of clinical pharmacology and therapeutics.

[26]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[27]  Honghui Zhou,et al.  PHARMACOKINETICS AND DISPOSITION Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis , 2009 .

[28]  M. Silverberg,et al.  Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis , 2009, Gut.

[29]  S. Travis,et al.  Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review , 2009, Inflammatory bowel diseases.

[30]  J. Gisbert,et al.  Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review , 2009, The American Journal of Gastroenterology.

[31]  K. Bendtzen,et al.  Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies , 2009, Scandinavian journal of gastroenterology.

[32]  P. Rutgeerts,et al.  Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease , 2008, Alimentary pharmacology & therapeutics.

[33]  P. Rutgeerts,et al.  Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. , 2008, Gastroenterology.

[34]  G. D'Haens,et al.  Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial , 2008 .

[35]  P. Rutgeerts,et al.  Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease , 2007, Gut.

[36]  K. Bendtzen,et al.  Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. , 2006, Arthritis and rheumatism.

[37]  M. Silverberg,et al.  Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[38]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[39]  M. Bala,et al.  Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[40]  N. Casadevall,et al.  Immunogenicity of recombinant human proteins: causes and consequences , 2004, Journal of Neurology.

[41]  P. Rutgeerts,et al.  Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.

[42]  M. Peppercorn,et al.  Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. , 2003, Gastroenterology.

[43]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[44]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[45]  A. Forbes,et al.  Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease , 2001, Gut.

[46]  C. Schaniel,et al.  Selection events operating at various stages in B cell development. , 2001, Current opinion in immunology.

[47]  K. Rajewsky.  Clonal selection and learning in the antibody system , 1996, Nature.

[48]  G. Tytgat,et al.  Tumour-necrosis-factor antibody treatment in Crohn's disease , 1993, The Lancet.